Stock Research for CNAT

CNAT

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

CNAT Stock Chart & Research Data

The CNAT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CNAT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


CNAT Due diligence Resources & Stock Charts

The CNAT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CNAT Detailed Price Forecast - CNN Money CNN View CNAT Detailed Summary - Google Finance
Yahoo View CNAT Detailed Summary - Yahoo! Finance Zacks View CNAT Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View CNAT Trends & Analysis - Trade-Ideas Barrons View CNAT Major Holders - Barrons
NASDAQ View CNAT Call Transcripts - NASDAQ Seeking View CNAT Breaking News & Analysis - Seeking Alpha
Spotlight View CNAT Annual Report - CompanySpotlight.com OTC Report View CNAT OTC Short Report - OTCShortReport.com
TradeKing View CNAT Fundamentals - TradeKing Charts View CNAT SEC Filings - Bar Chart
WSJ View Historical Prices for CNAT - The WSJ Morningstar View Performance/Total Return for CNAT - Morningstar
MarketWatch View the Analyst Estimates for CNAT - MarketWatch CNBC View the Earnings History for CNAT - CNBC
StockMarketWatch View the CNAT Earnings - StockMarketWatch MacroAxis View CNAT Buy or Sell Recommendations - MacroAxis
Bullish View the CNAT Bullish Patterns - American Bulls Short Pains View CNAT Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View CNAT Stock Mentions - StockTwits PennyStocks View CNAT Stock Mentions - PennyStockTweets
Twitter View CNAT Stock Mentions - Twitter Invest Hub View CNAT Investment Forum News - Investor Hub
Yahoo View CNAT Stock Mentions - Yahoo! Message Board Seeking Alpha View CNAT Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for CNAT - SECform4.com Insider Cow View Insider Transactions for CNAT - Insider Cow
CNBC View CNAT Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CNAT - OTC Markets
Yahoo View Insider Transactions for CNAT - Yahoo! Finance NASDAQ View Institutional Holdings for CNAT - NASDAQ


Stock Charts

FinViz View CNAT Stock Insight & Charts - FinViz.com StockCharts View CNAT Investment Charts - StockCharts.com
BarChart View CNAT Stock Overview & Charts - BarChart Trading View View CNAT User Generated Charts - Trading View


Latest Financial News for CNAT

Conatus Pharmaceuticals’ IDN-7314 Pan-caspase Inhibitor Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro and In Vivo
Posted on Wednesday April 18, 2018

Conatus Pharmaceuticals Inc. (CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the publication1 of results from both in vitro and in vivo studies of its pan-caspase inhibitor, IDN-7314, demonstrating reductions of hepatic tissue factor-driven coagulation. Patients with liver cirrhosis can suffer caspase-driven complications of both excessive bleeding and excessive clotting. The current studies suggest that a pan-caspase inhibitor may have the potential to reduce excessive clotting in patients with severe liver disease.


How Analysts Rate Regenxbio and Peers in April 2018
Posted on Friday April 13, 2018

Regenxbio (RGNX) is a clinical-stage biotechnology company focused on developing gene therapy product candidates to address genetic defects. The company’s product candidate RGX-314 is designed for the treatment of wet age-related macular degeneration (or wet AMD), which is a leading cause of total and partial vision loss in the US, Europe, and Japan. The other promising product candidate in Regenxbio’s pipeline is RGX-501 for the treatment of homozygous familial hypercholesterolemia (or HoFH).


Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis
Posted on Wednesday April 11, 2018

The biotech sector was in the news last week as shares of Spectrum surged on positive data from a phase II study while Incyte plunged on the failure of melanoma study.


Wired News – Conatus to Demonstrate Impact of Pan-caspase Inhibitor IDN-7314 in Reducing Inflammation and Liver Injury in Mouse Model of PSC at EASL Annual Meeting
Posted on Wednesday April 11, 2018

Stock Monitor: Titan Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 11, 2018 / Active-Investors.com has just released a free research report on Conatus Pharma Inc. (NASDAQ: CNAT ). If you ...


Enter a stock symbol to view the stock details.